Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMacarulla Mercadé, Teresa
dc.contributor.authorBlanc, Jean-Frédéric
dc.contributor.authorWang-Gillam, Andrea
dc.contributor.authorChen, Li-Tzong
dc.contributor.authorSiveke, Jens T.
dc.contributor.authorMirakhur, Beloo
dc.date.accessioned2021-03-19T12:33:13Z
dc.date.available2021-03-19T12:33:13Z
dc.date.issued2019-05-01
dc.identifier.citationMacarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, et al. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol. 2019 May 1;10(3):427–35.
dc.identifier.issn1879-4068
dc.identifier.urihttps://hdl.handle.net/11351/5777
dc.descriptionIrinotecan liposomal; Pacients grans; Càncer de pàncrees
dc.description.sponsorshipThe NAPOLI-1 trial (ClinicalTrials.govidentifier: NCT01494506) was sponsored by Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA; Medical writing support was provided by Laura McMahon of Physicians World Europe GmbH, Mannheim, Germany, and funded by Shire International, Zug, Switzerland. Correction and publication costs were funded by Global Medical Affairs, Servier, Suresnes, France.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJournal of Geriatric Oncology;10
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPàncrees - Càncer
dc.subjectMetàstasi
dc.subjectMedicaments - Administració
dc.subject.meshPancreatic Neoplasms
dc.subject.meshFluorouracil
dc.subject.mesh/administration & dosage
dc.subject.meshNeoplasm Metastasis
dc.titleLiposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.jgo.2019.02.011
dc.subject.decsneoplasias pancreáticas
dc.subject.decsfluorouracilo
dc.subject.decs/administración & dosificación
dc.subject.decsmetástasis neoplásica
dc.relation.publishversionhttps://linkinghub.elsevier.com/retrieve/pii/S1879-4068(18)30349-7
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Macarulla T] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Blanc JF] Pôle ADEN, Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France. [Wang-Gillam A] Division of Oncology, Washington University in St. Louis, MO, USA. [Chen LT] National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University, Tainan, Taiwan. Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan. [Siveke JT] Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. Cancer Consortium (DKTK, partner site Essen), German Cancer Research Center, DKFZ, Heidelberg, Germany. [Mirakhur B] Ipsen Biopharmaceuticals, Inc., Cambridge, MA, United States
dc.identifier.pmid30842038
dc.identifier.wos000470049200012
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple